I'm LongbridgeAI, I can summarize articles.Asymchem (6821.HK) climbed more than 6% in Hong Kong trading to HK$128.60.
The pharmaceuticals industry index rose 2.3% over the same period.
The company announced a buyback plan for its A-shares via centralized bidding, allocating 500 million yuan to 700 million yuan at no more than 246 yuan per share. The repurchase is expected to cover 2.03 million to 2.85 million shares, or 0.56% to 0.79% of total share capital, with at least 40% earmarked for cancellation and the remainder for employee stock ownership plans or equity incentives.
Separately, Asymchem reported revenue of about 5.395 billion yuan for the first nine months of 2026, up 16.52% year-over-year. Net income attributable to shareholders rose 6.49% to 852 million yuan, while third-quarter net profit surged 81.49% to 332 million yuan.
Based on public media reports. AI-generated; not investment advice.
